Floatz logo

PERIPHERAL BLOOD STEM CELLS, ALLOGENEIC, CD34 POSITIVE

Graft Versus Host Disease

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyCell therapyPhase 2/3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Graft Versus Host Disease cohort.

Asset / SponsorPhaseRating
BUSULFANUM
City of Hope Medical Center
Phase 4BBB
Cyclophosphamide
City of Hope Medical Center
Phase 4BBB
Thiotepa
Memorial Sloan Kettering Cancer Center
Phase 4BBB
Nivestim
City of Hope Medical Center
Phase 4BBB
Cyclosporin A
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 49 →

Same molecule, other indications

PERIPHERAL BLOOD STEM CELLS, ALLOGENEIC, CD34 POSITIVE is also rated in:

acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 2/3
74 / 100
View asset →
myelodysplastic syndromeActive
BB
Indicative · Phase 2/3
66 / 100
View asset →
chronic myeloid leukemiaDormant
BB
Indicative · Phase 2
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →